Zynex, a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, neurological diagnosis and cardiac monitoring, has received FDA 510(k) clearance for its NexWave medical device.
The NexWave device delivers three modalities of stimulation; traditional transcutaneous electrical nerve stimulation (TENS), interferential and neuromuscular electrical stimulation. The combined modalities of the NexWave provide a wide variety of pain and muscle rehabilitation therapies through one device.
Thomas Sandgaard, Zynex’s CEO commented, “We are very excited about the market introduction of this new product. The combined modalities of our NexWave provide doctors and clinicians a more comprehensive pain therapy solution for their patients. This device was designed with the patient in mind, as it is compact and easy to use, and falls under existing medical billing codes. We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary.”